AllianceBernstein’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-6,383
Closed -$98.8K 3273
2024
Q1
$98.8K Hold
6,383
﹤0.01% 3030
2023
Q4
$179K Hold
6,383
﹤0.01% 3000
2023
Q3
$304K Buy
6,383
+1,178
+23% +$89.9K ﹤0.01% 2800
2023
Q2
$499K Hold
5,205
﹤0.01% 2638
2023
Q1
$590K Hold
5,205
﹤0.01% 2481
2022
Q4
$583K Hold
5,205
﹤0.01% 2548
2022
Q3
$668K Buy
5,205
+560
+12% +$57.4K ﹤0.01% 2505
2022
Q2
$319K Buy
4,645
+810
+21% +$69.8K ﹤0.01% 2853
2022
Q1
$546K Buy
3,835
+15
+0.4% +$2.31K ﹤0.01% 2639
2021
Q4
$636K Sell
3,820
-2,950
-44% -$469K ﹤0.01% 2640
2021
Q3
$942K Buy
6,770
+2,430
+56% +$475K ﹤0.01% 2515
2021
Q2
$2.07M Buy
4,340
+385
+10% +$162K ﹤0.01% 2167
2021
Q1
$1.63M Buy
3,955
+105
+3% +$48.3K ﹤0.01% 2204
2020
Q4
$1.89M Buy
3,850
+675
+21% +$395K ﹤0.01% 2023
2020
Q3
$1.8M Sell
3,175
-1,795
-36% -$597K ﹤0.01% 1914
2020
Q2
$473K Buy
4,970
+870
+21% +$76.3K ﹤0.01% 2648
2020
Q1
$293K Buy
4,100
+700
+21% +$46.9K ﹤0.01% 2629
2019
Q4
$235K Hold
3,400
﹤0.01% 2866
2019
Q3
$273K Sell
3,400
-195
-5% -$12.9K ﹤0.01% 2836
2019
Q2
$232K Buy
3,595
+1,210
+51% +$115K ﹤0.01% 2917
2019
Q1
$328K Buy
2,385
+165
+7% +$20.1K ﹤0.01% 2716
2018
Q4
$201K Sell
2,220
-20
-0.9% -$2.8K ﹤0.01% 2888
2018
Q3
$340K Buy
2,240
+70
+3% +$11.3K ﹤0.01% 2787
2018
Q2
$373K Buy
2,170
+100
+5% +$16.3K ﹤0.01% 2722
2018
Q1
$304K Buy
2,070
+75
+4% +$14.4K ﹤0.01% 2693
2017
Q4
$405K Sell
1,995
-85
-4% -$17.5K ﹤0.01% 2601
2017
Q3
$667K Hold
2,080
﹤0.01% 2473
2017
Q2
$470K Buy
2,080
+450
+28% +$92.4K ﹤0.01% 2643
2017
Q1
$367K Sell
1,630
-90
-5% -$18.3K ﹤0.01% 2629
2016
Q4
$341K Hold
1,720
﹤0.01% 2690
2016
Q3
$423K Sell
1,720
-19,117
-92% -$6.71M ﹤0.01% 2585
2016
Q2
$12.1M Sell
20,837
-593
-3% -$348K 0.01% 841
2016
Q1
$11.4M Buy
21,430
+2,523
+13% +$1.32M 0.01% 830
2015
Q4
$13.3M Buy
+18,907
New +$12.4M 0.01% 809

Other funds holding MCRB

AllianceBernstein's MCRB Position: Q2 2024 in Review

AllianceBernstein sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 6,383 shares — an estimated $98.8K sold.

AllianceBernstein first reported a position in MCRB in Q4 2015 and held it in 34 quarters. The position peaked at $13.3M in Q4 2015. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • AllianceBernstein reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 6,383 Seres Therapeutics shares in Q2 2024, an estimated $98.8K.
  • AllianceBernstein first reported a position in Seres Therapeutics in Q4 2015 and held it in 34 quarters.
  • AllianceBernstein's Seres Therapeutics position peaked at $13.3M in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.